How do we “name” a cell and assign its identity? How do we know that we are all talking about the same cells? How do we agree on what it takes to confidently correlate previous with current research ...
The escalating cost of developing drugs is due, in part, to time spent assessing compounds that fail further down the drug discovery process. As such, high-content analysis (HCA) is now emerging as ...
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the ...
A low-profile child of the '60s, flow cytometry didn't capture the imagination of most researchers until the early 1980s. The decade saw the birth of the AIDS epidemic, and as attention focused on HIV ...
Larry Sklar (left) is a Distinguished Professor Emeritus at the University of New Mexico (UNM; NM, USA) whose interest in flow cytometry as a tool for drug discovery led to the development of ...
Research and development of monoclonal antibody (mAb) therapeutics is a vast and expanding area of drug discovery, largely due to mAb potential for high specificity and affinity towards target ...
Validated Assay Can Test for Interferon Activity in Pediatric Inflammatory Diseases Using Biomarkers
CHICAGO — The use of a clinically validated flow cytometry test can assess type 1 and type 2 interferon activity in children with various pediatric inflammatory diseases to evaluate and monitor their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results